Pharmacological enrollment of aldehyde dehydrogenase modulators to assist treating ischemia reperfusion-induced intestinal injury: is there a gap to be bridged?
- PMID: 28533269
- DOI: 10.1042/CS20170163
Pharmacological enrollment of aldehyde dehydrogenase modulators to assist treating ischemia reperfusion-induced intestinal injury: is there a gap to be bridged?
Abstract
This commentary highlights the research presented by Zhu et al. [1]. In this issue of the Clinical Science, the authors evaluated the protective effect of Alda-1 (a novel class of small molecule aldehyde dehydrogenase (ALDH2) activators) in the intestinal ischemia reperfusion (IR) injury. Remarkably, enhancing the ADLH2 activity by the use of Alda-1 can ameliorate several deleterious effects related to aldehydes, and may provide a better protection against an injury preestablished by IR. Together, an innovative metabolic strategy for treating patients with IR injury could be the use of ALDH modulators in a near future.
Keywords: ALDH; Alda-1; biobanking; ischemia reperfusion.
© 2017 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.
Comment on
-
Pretreatment with the ALDH2 agonist Alda-1 reduces intestinal injury induced by ischaemia and reperfusion in mice.Clin Sci (Lond). 2017 Jun 1;131(11):1123-1136. doi: 10.1042/CS20170074. Epub 2017 Mar 21. Clin Sci (Lond). 2017. PMID: 28325855 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
